These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 16580053)

  • 1. Prophylaxis and von Willebrand's disease (vWD).
    Abshire TC
    Thromb Res; 2006; 118 Suppl 1():S3-7. PubMed ID: 16580053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand's disease: clinical management.
    Federici AB; Castaman G; Thompson A; Berntorp E
    Haemophilia; 2006 Jul; 12 Suppl 3():152-8. PubMed ID: 16684011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis in von Willebrand disease.
    Berntorp E
    Haemophilia; 2008 Nov; 14 Suppl 5():47-53. PubMed ID: 18786010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Willebrand disease prophylaxis network (vWD PN): exploring a treatment concept.
    Berntorp E; Abshire T;
    Thromb Res; 2006; 118 Suppl 1():S19-22. PubMed ID: 16545435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inherited von Willebrand disease in 2006.
    Federici AB
    Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Desmopressin in hemophilia A and Von Willebrand's disease].
    Castro Cabezas M; de Graaf JC; Kraayenhagen RJ; Freen M; Poortman J; Hart HC
    Ned Tijdschr Geneeskd; 1991 Mar; 135(9):367-71. PubMed ID: 1901629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience of prophylactic treatment in von Willebrand disease.
    Lethagen S
    Thromb Res; 2006; 118 Suppl 1():S9-11. PubMed ID: 16616322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilic arthropathy in patients with von Willebrand disease.
    van Galen KP; Mauser-Bunschoten EP; Leebeek FW
    Blood Rev; 2012 Nov; 26(6):261-6. PubMed ID: 23010260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients].
    Kurth AA; Ludwig G; Scharrer I
    Orthopade; 1999 Apr; 28(4):366-74. PubMed ID: 10335531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
    Federici AB
    Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
    Berntorp E
    Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of urgent bleeding in von Willebrand disease.
    Gill JC
    Thromb Res; 2007; 120 Suppl 1():S21-5. PubMed ID: 17490729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.